Jim Roth - President, Chief Executive Officer, Director Mark Hussey - Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, IR Contact Officer.

Tim McHugh - William Blair Paul Ginocchio - Deutsche Bank Kwan Kim - SunTrust Randy Reece - Avondale Partners Kevin Steinke - Barrington Research.

Good afternoon ladies and gentlemen and welcome to Huron Consulting Group's webcast to discuss financial results for the fourth quarter and full year 2015. At this time, all conference call lines are on a listen-only mode. Later, we will conduct our question-and-answer session for conference call participants and instructions will follow at that time.

As a reminder, this conference call is being recorded. Before we begin, I would like to point all of you to the disclosure at the end of the company's news release for the information about any forward-looking statements that may be made or discussed on this call. The news release is posted on Huron's website.

Please review that information along with the filings with the SEC for a disclosure of factors that may impact subjects discussed in this afternoon's webcast. The company will be discussing one or more non-GAAP financial measures.

Please look at the earnings release and/or on Huron's website for all of the disclosures required by the SEC, including reconciliations to the most comparable GAAP numbers. And now, I would like to turn the call over to Jim Roth, Chief Executive Officer and President of Huron Consulting Group. Mr. Roth, please go ahead..

Good afternoon and welcome to Huron Consulting Group's fourth quarter and full year 2015 earnings call. With me today is Mark Hussey, our Chief Operating Officer and Chief Financial Officer. This is our first earnings call since the sale of Huron Legal. So we will focus most of our discussion on Q4 results based on continuing operations.

Huron's full year revenue from continuing operations increased 11.4% over the prior year driven by solid performance from Studer Group and strong results in our Education and Life Sciences and Business Advisory segments. I will spend a few minutes talking about our fourth quarter and full year 2015 results before I discuss our expectations for 2016.

Fourth quarter and full year Healthcare revenue grew approximately 8% year-over-year, driven primarily by Studer Group.

Our revenue cycle practice turned in another year of solid results while our performance improvement costing [ph] clinical solutions, as we now referred to it, as remained flat compared to the third quarter and at levels below our initial targets.

As part of the market facing adjustments that we referenced in October, we recently combined our performance improvement and clinical practices to be more responsive to the increasing need for hospitals to gain greater insight into the cost of care and ultimately modify their clinical operations to improve the cost and efficiency of delivering care.

As many hospitals take on or consider risk-based contracts, it becomes increasingly critical to understand and improve the cost of care. Combining our performance improvement and clinical practices will better align our services with these emerging client needs.

Our Education and Life Sciences or ELS business concluded 2015 on a strong note with 15.1% revenue growth on a full year basis over 2014 results. ELS performed strongly in the first quarter of 2015 and each practice within this business maintained momentum and performed well throughout the year. The fourth quarter was no exception.

Within ELS, our higher education practice, which is made up of our strategy and operations, technology and research solutions, saw continued strong demand and throughout the year, we made solid progress in expanding new services and offerings to our higher education clients including our client-based ERP services.

Our Life Sciences practice also had the best year in its history. I am pleased that all of the solutions within the ELS segment achieved such strong performance throughout 2015 responding very effectively to the many complex challenges facing the higher education and life sciences industries.

Our business advisory segment also turned in a strong fourth quarter and year, achieving a full year revenue growth rate of 32% year-over-year with record breaking performances from for both of our legacy business advisory practice and the enterprise performance management and analytics or EPM&A practice.

These businesses are an important part of Huron's growth strategy and each practice finished the year with increased margins and strong prospects for the future.

The business advisory and EPM&A practices provide advisory, operational improvement and technology services to large and middle-market commercial clients across multiple industries, including financial services, energy, manufacturing, technology and retail enabling Huron to expand our market horizons.

Equally important, both practices work collaboratively with our Healthcare, Education and Life Sciences clients providing new avenues of products and services to clients in our largest industry verticals.

Before I provide my comments on 2016, I would also like to highlight that earlier this month we closed our acquisition of MyRounding, a Denver-based firm that specializes in creating digital health solutions to improve patient care.

MyRounding provides technology solutions that help hospital and healthcare organizations increase levels of quality, patient safety and satisfaction throughout the continuum of care.

By combining Huron's advisory expertise with MyRounding's technology development and service delivery, we will be uniquely positioned to further expand our portfolio of solutions to enable our clients to implement and sustain improvement across their organizations. We are thrilled to welcome MyRounding to the Huron team.

Now let me turn to our expectations and guidance for 2016. Revenue guidance for the year is $720 million to $760 million and adjusted diluted earnings per share guidance is $3.20 to $3.40. The midpoint of our guidance reflects mid single-digit revenue growth and low double-digit EPS growth.

While we will provide more commentary during our Investor Day on Wednesday, I want to provide color on a few aspects of this guidance. First, having sold our Huron Legal business at the end of the year, we now expect less variability in Huron's financial performance.

While the legal business provided tremendous value to its clients, the practice had challenges with revenue growth over the past several years, which tended to mask the growth story of our remaining segments. Excluding the legal segment, annual revenue growth from continuing operations and all other segments has averaged 13% over the past five years.

Secondly, our primary industry verticals healthcare, higher education and life sciences continue to undergo dramatic transformation.

Whether as a result of government regulation, pricing and cost pressures or evolving business models, these three industry verticals provide tremendous opportunities for us to assist our clients in successfully navigating their industrywide challenges.

We do not expect the underlying dynamics creating these industry pressures to ease or the pace of transformation to recede in the foreseeable future. The reputation we have achieved on the scale services that we offer within these industry verticals has positioned Huron very well for solid future growth.

Focusing on our growth expectations for each segment, we anticipate the Healthcare practice will achieve low to mid single-digit revenue growth in 2016 with most of the growth been driven by Studer Group.

We expect our revenue cycle business will continue to grow and while demand for our cost and clinical solutions has stabilized, we are cautious about predicting when new large integrated engagements will emerge to support the ongoing strength of the traditional core of our Healthcare business.

While historically our healthcare engagements have averaged between $8 million and $10 million, over the past three years we have had several very large engagements that supported revenue growth in excess of our traditional averages. As we look to the future, some of the larger engagements that will tailoff this year will need to be replaced.

We have opted to be conservative with our revenue guidance until we get more visibility into the market demand and timing for these large integrated projects. Given our conservative growth expectations in our cost and clinical practice during the coming year, we enter 2016 cautiously optimistic about the overall growth of the Healthcare segment.

We have spent considerable time on prior calls discussing the potential reasons for the downturn in our cost and clinical practice in the second half of 2015.

But the primary rationale for our cautious optimism this year is that the operating environment for most not-for-profit hospitals remains challenged with margin growth expected to be flat or negative.

Given the outlook of most healthcare industry commentary and the overarching economic backdrop of this country, our view remains that healthcare providers will see continued cost pressures that exceed any increases in volume based revenue resulting in a negative outlook for hospital margins.

How this plays out remains to be seen but our sense is that the market demand for our services will grow in 2016 and beyond, however we will remain cautious about the timing of growth in the cost and clinical solutions until we see evidence of hospital financial challenges translating into increased demand at levels supporting our desired growth rates of this practice.

Our 2016 guidance reflects expected mid to upper single-digit revenue growth for our ELS segment. The same industry issues that led to a strong 2015 for the segment continued to be at issue in 2016. Similarly, we expect mid-teen revenue growth for our Business Advisory segment.

We believe this segment is likely to achieve the highest percentage growth in the company for the second straight year. In summary, we are projecting modest growth in Healthcare and solid growth in our ELS and Business Advisory segments.

Despite the cautious view for Healthcare, we expect our companywide revenue growth to be within the mid to upper single-digit range that we have set for our long-term corporate objectives. Finally, as Mark will discuss shortly, we generated $164 million of cash flow from operations in 2015 and expect continued strong cash flow in 2016.

We are well positioned to continue our strategy of acquiring small to midsize businesses within each of our three segments and to make internal investments capable of yielding solid financial returns.

In closing, I want to note that our 2015 performance could not have been achieved without the efforts of the tremendous team of people that work at Huron.

As a professional services firm, our business is only as good as our people and our success is directly attributable to the highly talented and passionate team that makes Huron a great place to work. With their unwavering focus on our clients and the strong reputation that they have built in the markets, we are well poised to continue our success.

I look forward to the bright future that lies ahead for Huron. Now let me turn it over to Mark for a more detailed discussion of our financial results.

Mark?.

Thank you, Jim and good afternoon everyone. Before I begin, please note that I will be discussing non-GAAP financial measures such as EBITDA, adjusted EBITDA, adjusted net income and adjusted EPS.

Our press release, website and 10-K each have reconciliations of these non-GAAP measures to the most comparable GAAP measures along with a discussion of why management uses these non-GAAP measures.

Also, as a result of our previously announced divestiture of Huron Legal, which closed in December, the Huron Legal segment will be treated as a discontinued operation for full year 2015 and all historical periods presented.

Please note that immediately following our press release today, we issued an 8-K with restated quarterly results for 2014 and 2015. This information is also posted on the website. In addition, our previously announced acquisition of MyRounding, which closed in February, is not included in our fourth quarter financial results.

MyRounding will be included within our Healthcare segment beginning in the first quarter of 2016. Now I will walk through some of the key financial results. Revenues from continuing operations for the fourth quarter of 2015 were $185.1 million, up 12.9% from $163.9 million in the same quarter of 2014.

Revenues for the fourth quarter of 2015 reflect our acquisitions of Studer Group, Rittman Mead India and Cloud62, which in aggregate generated $25.1 million of revenues during the quarter.

The year-over-year increase in revenue is primarily attributable to our acquisition of Studer Group and strong performance in our Education and Life Sciences and Business Advisory segments. Operating income from continuing operations increased $15.1 million or 69.7% to $36.7 million in Q4 2015 compared to $21.6 million in Q4 2014.

Operating margin was 19.8% in Q4 2015 compared to 13.2% in Q4 2014. Adjusted EBITDA from continuing operations was $40 million in Q4 2015 or 21.6% of revenues compared to $28.8 million in Q4 2014 or 17.6% of revenues.

On a full year basis, adjusted EBITDA from continuing operations as a percentage of revenues increased to 19.9% compared to 17.6% in 2014. Net income from continuing operations was $32.5 million or $1.44 per diluted share in the fourth quarter of 2015 compared to $10 million or $0.44 per diluted share in the same quarter of last year.

Q4 2015 was favorably impacted by a one-time tax benefit of $12.3 million or $0.55 per diluted share. This tax benefit resulted from the company's check-the-box election to treat two of our wholly-owned foreign subsidiaries as disregarded entities for U.S. federal income tax purposes.

Let me pause for a moment to discuss the tax benefit in just a bit more detail. In 2015, we elected to close our Saudi Arabian and Dubai operations, which led to the check-the-box election.

Looking ahead, we will continue to look for growth opportunities internationally, including expanding our presence in India, which is primarily being served by our Rittman Mead India team.

Adjusted non-GAAP net income from continuing operations was $21.1 million or $0.94 per diluted share in the fourth quarter of 2015 compared to $13.6 million or $0.60 per diluted share in the same period of 2014.

For the full year 2015, adjusted on non-GAAP net income from continuing operations was $67.6 million or $2.99 per share compared with $56.1 million or $2.45 per share in 2014. These results are consistent with the updated ranges provided at the time we announced the divestiture of our legal business on December 10.

Our effective income tax rate from continuing operations in the fourth quarter of 2015 was 0% as a result of the company's check-the-box election. Excluding the impact of this tax benefit, our effective income tax rate was 38.1% in Q4 2015.

This is lower than the statutory tax rate inclusive of state income taxes primarily due to tax credits and incentives.

Our effective income tax rate from continuing operations in the fourth quarter of 2014 was 44.1%, which was higher than the statutory rate inclusive of state income taxes primarily due to foreign source losses with no tax benefits and an increase in valuation allowances.

On a full-year basis, our 2015 effective tax rate was 25.9% inclusive of the one-time tax benefit. On a normalized basis, excluding the nonrecurring tax benefit, our effective tax rate was 40.7%.

Please note that when comparing prior-year periods our tax rate has changed as certain tax credits and elections such as our 2014 check the box election related to our U.K. entity were related to the legal segment and therefore are reported as discontinued operations.

Now I will make a few comments about the performance of each of our operating segments. The Healthcare segment generated 63.8% of total company revenues during the fourth quarter of 2015. The segment posted revenues of $118.3 million for the fourth quarter of 2015, up $8.8 million or 8% from the fourth quarter of 2014.

Revenues for the fourth quarter of 2015 included $23.9 million from our acquisition of Studer Group. Excluding Studer Group, organic revenue decreased 13.8% compared to the year ago quarter primarily due to lower performance-based fees and a decrease in revenue from our cost and clinical practice.

Performance-based fees in Q4 2015 were $12.6 million compared to $33.2 million in the same quarter last year. On a full-year basis, Healthcare revenue increased 7.5% including the impact of the Studer Group acquisition which added $79.9 million to 2015. On an organic basis, revenue decreased 11.7% for the year.

Performance-based fees for the full year 2015 were $52.3 million compared to $103.2 million in 2014. Operating income margin for Healthcare was 40.1% for Q4 2015 compared to 38% for the same quarter in 2014. The increase in margin was primarily due to lower bonus expense as a percentage of revenues.

As expected, utilization in this segment sequentially improved in the fourth quarter. Utilization was 82.7% in Q4 2015 compared to 81.1% in the third quarter of 2015. The Education and Life Sciences or ELS segment generated 23.3% of total company revenues during the fourth quarter of 2015.

The segment posted revenues of $43 million in Q4 2015, up $4.9 million or 12.9% from the fourth quarter of 2014. On a full-year basis, ELS revenue increased 15.1% versus the prior year. As Jim mentioned, the Education and Life Sciences practices both performed well and saw strong demand across all solution areas within each business.

The operating income margin for Education and Life Sciences was 20.4% for Q4 2015 compared to 22.5% for the same quarter in 2014. Utilization for the fourth quarter of 2015 was 74.4% compared to 74.2% reported in Q4 2014.

The decline in margin was primarily driven by our investment in cloud-based ERP capabilities reducing margins approximately 200 basis points in the fourth quarter. On a full year basis, operating margin was 26.3% compared to 24.8% in 2014. The Business Advisory segment generated 12.9% of total company revenues during the fourth quarter of 2015.

The segment posted revenues of $23.8 million in Q4 2015, up $8.1 million or 51.2% in the fourth quarter of 2014. Both our legacy Business Advisory and EPM&A practices delivered very strong results in the quarter. On a full year basis, the Business Advisory segment revenues grew 32% year-over-year.

The legacy Business Advisory practice grew 22.4% in 2015, while the EPM&A practice grew 42.6% in 2015, including revenue from the Rittman Mead India acquisition in July 2015 and the Cloud62 acquisition in October 2015. On an organic basis, EPM&A revenue growth was 37% on a full-year basis.

The operating income margin for the Business Advisory segment was 24.2% for Q4 2015 compared to 12.4% for the same quarter in 2014. On a full-year basis, operating margin was 23.2% compared to 22.3% in 2014. Other corporate expenses not allocated at the segment level were $18.4 million in Q4 2015 compared with $25.7 million in Q4 2014.

The decrease was primarily due to a gain of $10 million from a legal settlement in Q4. Also included corporate and corporate expenses not allocated at the segment level is $2.4 million of Studer Group's costs. Now turning to the balance sheet and cash flows.

On a total company basis, including discontinued operations, DSO came in at 62 days for the fourth quarter of 2015 compared to 74 days for the third quarter of 2015. Excluding Huron Legal, DSO was 56 days at year-end.

Total debt includes both the $250 million face value of convertible notes and $92 million in senior bank debt for a total debt of $342 million. We finished the year with cash of $58 million or net debt of $284 million.

This was $154 million improvement over Q3 2015 and an increase of $148 million compared to year-end 2014 as we used some proceeds from sale of Huron Legal business to pay down debt. Our leverage ratio at year-end, defined as total debt net of cash, was approximately two times adjusted EBITDA. Cash flow from operations for the year was $164 million.

In 2015, we used our cash to invest $355 million in acquisitions including our acquisition of Studer Group and further investments in Shorelight, almost $35 million in share repurchases and $18 million in capital expenditures. Free cash flow for 2015 was $146 million. Now let me summarize the guidance that was included in our press release.

Our recent acquisition of MyRounding is included in our guidance range and is not material to full year results.

With that said, for the full year we anticipate revenues before reimbursable expenses in a range of $720 million to $760 million, EBITDA in a range of $136 million to $145.5 million, adjusted EBITDA in a range of $138 million to $147.5 million, net income in a range of $45 million to $50 million, adjusted non-GAAP net income in the range of $68.5 million to $73.5 million and finally GAAP EPS between $2.10 and $2.30 and adjusted non-GAAP EPS in a range of $3.20 to $3.40.

Assuming the midpoint of our guidance range, we expect cash flows from operations of approximately $145 million. Capital expenditures are expected to be relatively flat at approximately $18 million to $20 million.

Our capital expenditures in 2016 primarily consist of spending on leasehold improvements in two of our larger offices driven by the timing of lease expirations along with expansion of a new office in Bangalore, India. Capital expenditures for Huron Legal in 2015 were substantially reduced pending the outcome of the sale transaction.

Weighted average diluted share counts for 2016 are estimated to be 21.5 million. The guidance assumes share repurchases only to the extent that have already been completed as of the date of this call. Through today, we have repurchased 1.3 million shares in Q4 2015 and Q1 2016 at a total cost of approximately $76.3 million.

We have $35.1 million remaining under $125 million authorizations. To be clear, our guidance does not assume any further share repurchases that may occur throughout the year under our current $125 million authorization. Finally with respect to taxes, you should assume an effective tax rate of approximately 41%.

Now let me add some color to our guidance starting with revenue. The midpoint of the revenue range reflects a 5.9% increase from 2015 revenue of $699 million. Embedded in the guidance range are expected performance-based fees in the Healthcare segment in a range of $55 million to $65 million.

As Jim mentioned, we are cautiously optimistic about our Healthcare business in 2016. Our outlook for the Healthcare segment is for revenue growth in the low to mid single digits. We expect legacy Healthcare revenue growth to be in the range of flat to low single digits and Studer Group growth in the high single digits.

We expect our revenue cycle and Studer Group businesses to continue to perform well while we continue to make adjustments to reflect the changing market for our cost and clinical solutions, which represents approximately a third of our healthcare business.

We expect 2016 Healthcare operating margins to be approximately 37%, reflecting investments in new service lines including the continued growth of our healthcare strategy practice. In Education and Life Sciences, we expect mid to upper single-digit revenue growth for 2016 and we expect operating margins will be approximately 24%.

In the technology practice within our higher education business, Jim mentioned our investment in cloud-based ERP capabilities. We expect 2016 segment operating margins to include approximately 300 basis points of investment reflecting the hiring, training and other additional expenses to expand this initiative.

In Business Advisory, we expect to see low double digits to mid-teen revenue growth for 2016 and we expect to maintain our operating margins in the segment. Turning to the total company, Huron's adjusted EBITDA margin is expected to be in a range of 19.2% to 19.4%, a decrease of 50 to 70 basis points compared to 2015.

This primarily reflects investments in initiatives I just discussed. Our 2016 adjusted EPS at the midpoint of the range of $3.30 reflects growth of 11% and includes approximately $0.15 per share, for the impact of the cloud-based ERP investment expenses I just mentioned.

In summary, our financial strategy is to pursue mid to upper single-digit organic growth over time. In 2016, our adjusted EBITDA margins are expected to be lower than the prior-year for the first time in five years before the impact of reclassifying the legal business to discontinued operations.

This primarily reflects investments we are making in new service lines as well as the timing related to adjusting our corporate SG&A expenses to align with the lower revenue base following the divestiture. We continue to remain committed to margin expansion of 20 to 30 basis points per year over time.

Other than the impact of investments we make in the form of operating expenses, we generally expect our practice margins to remain relatively steady with productivity gains and to a lesser extent, pricing, offsetting wages and other costs.

We continue to expect margin expansion to be primarily driven by total company revenue growth at a faster pace than SG&A expense growth for our corporate overhead expenses. We expect our strong free cash flows to continue to provide an important source of growth and value for our shareholders.

For 2016, we expect free cash flow of approximately $125 million. Our primary uses of free cash flow will continue to be complementary acquisitions that we expect will augment our growth over time. Our deal pipeline remains active with opportunities at various stages of the pipeline.

We expect M&A will continue to be a meaningful contributor to our overall results in 2016 and beyond. As a secondary use of cash, we expect to selectively repurchase shares from time-to-time under our remaining $35 million authorization. Our balance sheet is in excellent shape.

We ended the year with the lowest DSO achieved in at least five years and along with strong free cash flow, our leverage, borrowing capacity and relatively low cost of capital provide a significant flexibility to achieve our objectives.

As a closing reminder, with respect to adjusted EBITDA, adjusted net income and adjusted EPS, there are several items that you will need to consider when reconciling these non-GAAP measures to comparable GAAP measures. The reconciliation schedules that we included in our press release will help you walk through these reconciliations.

Thanks everyone and now I would like to open up the call to questions.

Operator?.

[Operator Instructions]. Our first question comes from the line of Tim McHugh of William Blair. Your line is now open. Please proceed, sir..

Yes. I guess first a question on the margins. I understand the ERP investment, but I would like a little more color there, especially since I think you already had talked about it being in investment mode in 2015.

And then secondly, I guess I am just still trying to bridge, you had given in December pro forma for the sale of legal that after taking out some corporate costs you would be 21.5% EBITDA margins or so. And so a little over 200 basis point difference versus what you are guiding to, so I am trying to bridge that gap..

Yes. Tim, this is Mark. I will leave Jim to elaborate on ERP initiative, but let me start on the bridge side. I think there's probably three main components. One on healthcare on the margins. We finished this year at 38.2% operating margin for the segment. The comment I just made on the guidance is for margins of above 37%.

So if you think that delta on an expected revenue, you probably have somewhere between know $5 million, $5.5 million impact and that really frankly relates to a couple of things. One is the buildout of the strategy practice. In the second half of 2015, we started hiring new managing directors and continued to expand that initiative into 2016.

I think the other thing that is also an element here is, on the mix with contingent fees.

And while 2015 contingent fees were at a similar level or maybe just a little bit lower than what we saw that we are guiding to in 2016, the reality is that we had expected them to be higher and to some degree that impact ended up being covered more than offset in bonus expense the way our plan works.

And so to some degree, there is a little bit of a mild headwind on those being more milestone-based in 2016 on the healthcare margins. In the ELS and again I will have Jim elaborate here but essentially what we talked about was an expansion of the initiative and really what you have two pieces, Workday and then Oracle piece.

The Workday is really an expansion. And so what we had talked about initially was that we thought in 2016 Workday would likely be more of a breakeven and I think that will continue to be the case in terms of our expectation. On top of that, there is additional investment because we have the same opportunity really in the Oracle side of the business.

And so collectively when you look at those, the roughly 300 basis points on the ELS margins end up being again in that similar range of say, $5 million, $5.5 million.

And then finally on the corporate cost, there is some element of timing here as we work through just the transition of selling what is a business that's twice as large as the acquiring entity. So their ability to immediately take on and start those causes has some gap in terms of what we thought we were going to be able to do relative to timing.

Although I think that will quickly dissipate after Q1 and maybe into Q2. So those are probably the three big impacts and I would say you probably in the low single digit millions of dollars, $3 million roughly of impact on the corporate side.

So collectively those are the big ticket items that really would bridge you from where we thought we were going to be and again we had not completed our full budget cycle at that point for where we now see 2015.

And finally, just the others, there is some element of conservatism in that outlook because like in the ELS, mid to upper single-digit guidance, as an example, we are expecting some positive growth in the mid single millions of dollars in Workday, but that will be at breakeven.

So part of that is mix and so if you take that piece of it out of that mid to upper single-digit growth, we are probably being a pretty conservative in the outlook.

Jim, do you want to add to the comments on ERP?.

Yes. Tim, the only thing I would add at this point is that we announced in 2015 that we are going to be making the investment in Workday and we had anticipated certain growth trajectory for that part of the business.

And I think pretty early on, we realized that some demand in the market for those kinds of services that is basically people that know and understand the cloud software that was being offered and have the knowledge and awareness of higher education and healthcare background were going be in very solid demand.

So actually our investments are proving and are even better than we had thought they were going to. We feel really good about the way we have been positioned in this part of the business.

And it give us that much more incentive to continue to grow and expand because we believe that for the foreseeable future, there is going to be a very strong demand and we are uniquely qualified to do this kind of work.

The advantage is, a large part of it is what's driving is particularly in the higher education space is that organizations are using this as an opportunity to completely restructure the way they do business and that gives us a great opportunity to do very sizable process redesign work in conjunction with helping them implement the cloud-based solution.

So we continue to view this as a very strong part of our growth strategy for the ELS business and we hope that it will also expand into the healthcare business as well..

Okay. And then just a follow-up, performance improvement, your introductory comments basically said that you don't think it's that hospitals are lacking for margin pressure.

The more you have dug into it, what's the challenge there for you if it's not that the market has changed such that they are not looking for help there?.

Well, Tim, it's been a little bit of a mystery to us. So we can conjecture part of it, I think it still revolves around timing.

I think there were certain hospitals in 2015 that had some what we believe to be temporary relief from added volumes from ACA and that that gave them some basis for wanting to delay any of the hard effort that's required where you are to go through a cost reduction.

And so I think a lot of these hospitals, it's not as though they have never done cost reduction before, they had done it over a period of three or four years.

They finally found an opportunity that where there might be a little bit of a breather and I think many of the hospitals, we felt, were just waiting to see whether they could delay this any further and I think some of them did. That's our sense. We don't believe this is a competitive positioning issue for us at all.

We believe that, at least for the target clients that we have, this is more of an issue of just wanting to not undertake the somewhat invasive performance improvement efforts until they absolutely have to and I think in 2015, there was a sense that at least some places didn't absolutely have to.

So I think clients are also buying differently in the sense that they are probably, at least now, focused a little bit more on some of the more small targeted projects rather than the comprehensive integrated projects. And that, too, has had an impact on the way they are buying from us. So I think we are continuing to be patient with our clients.

And as we have indicated, we think that there are numerous reasons to believe that the economics for our hospital clients are going to be challenging at best in 2016 and we are well prepared to address those demands when they come up.

What we didn't want to do and the reason that our guidance is conservative is we did not want to begin to predict the timing of that emergence, even though we feel fairly strongly that it will emerge. We just don't want to get into a timing discussion on that..

Does the pipeline for that practice look any, even if the revenue is not different, if we assume pipeline today versus I guess in the fall, has that looked better yet?.

The pipeline remains strong. I think what we are seeing is the lack of some of the really large integrated projects that have helped put some wind in our sales in the past. So in terms of just the raw number of data points, the number of clients that we have, I think the demand still is very strong.

The issue for us is just the size of some of these projects that just our clients are just buying differently and they are taking a more focused approach to what they want to do. And on top of that, as we have said before, there, their needs are changing as well.

Some have moved on and have done all the performance improvement work they need to do and they are now more focused on things like population health and understanding cost of care. And so the market has changed. We referenced that back in the last part of last year and we are continuing to respond to that. So our pipeline remains decent.

What we don't have right now and particularly in the larger health systems and the larger academic medical centers, we don't have visibility into the large projects that we typically had. We do believe that they are going to be there. There is considerable stress in the system right now.

But rather than figure out or try to predict when the timing of those are going to come around, we decided to take a cautious view given our current lack of visibility for some of those larger engagements. I think the underlying core traditional business that we have looks good in terms of the number of clients we have.

It's just the size of some of the engagements is smaller and we don't have the much bigger projects that we typically had help us boost some of our revenues..

And just a follow-up related to that. You referenced risk of large projects rolling off. I thought at least some of the big ones you talked about last year didn't start until the middle of last year. And given they were bigger and longer, I would have thought that continues, that that would have been more of a 2017 issue..

As we have said before, Tim, it's not one project on any one of our, for example, on a large project, it may have eight or nine projects that are part of it. And so what happens is, some of the projects have peaked, others are still going and we will continue to go into 2017 and maybe beyond. But some of the larger parts of those projects have peaked.

It's not just where the whole project ends fully in one day. We have some things that pick up at the beginning, some things that begin later in the cycle. Some of the earlier projects are now beginning to tailoff while others continue..

Okay. Thanks..

Thank you. Our next question comes from the line of Paul Ginocchio of Deutsche Bank. Please proceed, sir. Pardon me, Paul. Your line is now open..

Sorry about that. Hi Mark, apologies.

Can you give us some color on acquired revenue for 2016 and maybe some color on MyRounding? And then second, Jim, is the performance improvement, when you are talking about performance improvement, does it still hold true for clinical transformation? And I thought clinical transformation was sort of the fastest growing area.

Is it concern in the marketplace about ACA or changes or things not going to happen? Is that what's causing people to pause if that is an issue? Thanks..

Yes. Let me start on that, Paul, so color on acquired revenues. Obviously, let me start with MyRounding since that deal happened. MyRounding is actually a business that we had a relationship, actually Studer, prior to our deal going back to the middle of 2014. And they co-developed a rounding product to use in connection with their clients.

That quickly ended up going to market. It was pretty successful. It ended up on a combined basis between Studer, who was private labeling it and MyRounding who was selling it separately, ended up getting to roughly about 85 clients and low double digits millions of dollars of TCV for a SaaS-based product.

So for us, it was a natural extension of a relationship we already had. I would tell you that there was a defensive element to acquiring that business as well as an offensive with respect to being able to deal do more with that product development capability. So at the end of the day, that one is the story behind MyRounding.

But when you look at the acquired revenues, if you take Studer out of the mix, you really have an average sized deal that we have been doing probably in the range of two or three deals a year. And again, who can predict when they can come, because you never know as we all know with acquisitions.

But really, even our of our $125 million of free cash flow, we think we will have conservatively, we believe that there will be some meaningful number.

I don't want to put a number on it, for disclosure purposes, but I would tell you that I would be surprised if we ended the year without more than this one deal that we have already done because of just the strength of the pipeline and I think those generally for us have been good accretive deals. We talked about the criteria that we look for.

It really starts with an ROI, usually in the mid to upper teens is realistic, we think, in this marketplace for the kind of businesses that we are looking for. Oftentimes, they are founder-based companies that are looking for a platform to expand.

We certainly have run that play with our EPM&A business and they have a lot of success to-date integrating them. But there's others out there as well in each one of our practice areas, probably with the exception of legacy business advisory, has various deal opportunities in certain stages.

So I think it's reasonable expect, even though we wouldn't put it in the guidance or be specific about the timing that there will be some deal close this year..

Paul, this is Jim. Let me take a shot at trying to respond to the second part of your question, if I understood it correctly. Let me just give you two minutes or one minute of background.

Historically, we have had a business in healthcare called performance improvement and that essentially was cost-reduction effort, sometimes in the clinical area, sometimes in the administrative areas.

We also then had a practice that you are correct in referring to the fact that it was called the clinical transformation and that was really helped at focusing more on helping the clinical operations transform into improved operation, more collaboration of care, things of that nature.

And toward the middle part of 2016 as we continue to see changes in the marketplace, we realized that issues like the cost of care which was becoming increasingly important, particularly in a risk environment, required those practices really to be working more closely together that if you are trying to transform the clinical operations, you should be doing it in conjunction with some strategy.

So we changed the emphasis and combined the two practices, really to focus on what we believe is to be one of the emerging issues and that is to have our hospitals better understand the cost of care and our view of the cost of care involve both the clinical transformation piece and the performance improvement piece.

So it's a long way of saying that you are right, the clinical piece was actually a fast growing area. We combined it not out of weakness but more out of a response to market needs in terms of what they were looking for to help them with this kind of more urgently evolving practice.

Keep in mind, under a fee-for-service environment, the cost of care wasn't all that important. As you begin to transition away from that, it suddenly becomes much more important.

And I think what we are seeing is, I wouldn't describe the transition away from value from a fee-for-service to be rapid, but it is still emerging and more and more hospitals are focusing on the overall cost of care. We felt combining the practice put us in a better position to respond to their needs..

So you are still seeing demand for that clinical transformation more so than you are seeing demand for [indiscernible]..

Absolutely. We still have strong demand. The demand for what we are now calling the cost in clinical solutions, it still has a lot of activity. We are at the point where the jobs are a little bit slower right now. And as we said, we are lacking visibility on some of the larger fully integrated projects.

But the need is there and the need is particularly acute in some of the areas that we have traditionally worked in and that is the larger health systems and the academic medical centers where, as we have said before, there is a unique set of circumstances that make it even more difficult to achieve the objectives.

So there's no question there is demand. What we are trying to do is to get back to the growth rate that we have historically had. And whereas historically we have had better visibility in healthcare into the future because of some of the size of the larger projects, we don't have that visibility today.

And that's what's making us cautious about our guidance for healthcare in 2016..

Thank you..

Thank you. Our next question comes from the line of Tobey Sommer of SunTrust. Please proceed, sir..

This is Kwan Kim, on for Tobey. Thanks for taking my question. I have a follow-up on Workday implementation projects.

How would you characterize the progress you have made so far with regards to your prior expectations? Could you give us an update?.

Yes. We are actually making better progress than we had anticipated. We have probably more clients that are active at this point in time than we had. Those projects are still emerging, but they are active.

We have more people trained than we had thought we would have at this point in time, which is clearly a factor of our view of the demand in the marketplace. And we have the prospects and our success in the marketplace is probably also ahead of where we thought we would be, recognizing that this practice is relatively new for us.

We know and understand, particularly in higher education, we understand the business so incredibly well. And the fact that we can get our people up and trained very readily, the fact that we can hire experienced people in this area, has built us a competency and a degree of depth in this business that I think has surprised a lot of people.

And we have been successful with our clients who now see and realize the depth of experience that we have, not just in Workday but also in the higher education setting. So that's why we have got very strong hopes for the future growth of this business..

And this is Mark. Let me just add that, the investment that we ended up making which, again just to remind everybody, is in a form of OpEx, ended up being about 170 basis points in 2015, which is less than we had expected. So I think we had good results with a little bit less investment.

And even as we talk about the cloud investments going ahead, the cloud in general is also, when we think about our EPM&A business, one of the major opportunities that organically is creating lots of opportunity.

So there is a broader theme here, but ultimately when we get into the implementation expansion, we will hopefully have been conservative in terms of what we expect to happen..

Okay. Thank you for the color. And in the Business Advisory segment, regarding restructuring work, what is your expectation for demand in 2016? And which industries are contributing to this demand? Any comments on what you are seeing? Thank you..

This is Mark. I think it's going to be no surprise in terms of the industry that we are seeing, but in general, the easy answer is oil and gas where you see it across the board, but I think for us, we are more of a generalist practice and just as you see the junk buying markets are starting to really tighten up.

There is a lot of companies that are trying to get ahead of that, either through restructuring or you if the markets are going to be quite open, figuring out what their alternatives are.

So I think for the legacy Huron Business Advisory segment, the combination of the strong restructuring practice along with the broker-dealer capabilities that we added in 2014 will continue to produce a good combination of growth.

And so, you we definitely are having an expectation for them to be a in a double digit range of growth in 2016 as well as our EPM&A practice..

Got it. Thank you..

Thank you. Our next question comes from the line of Randy Reece of Avondale Partners. Please proceed..

Good afternoon. The consultant headcount in healthcare was a little bit less than we had expected and I was wondering if you could maybe give us a little bit of a feel of how you expect the revenue and headcount trends to play out sequentially through the year, what you have assumed in your guidance.

I am just trying to get an idea to know how slowly the year will start and how you expect it to pick up through year?.

Yes. Randy, I actually think so looking at 2015, we actually had a very, very slow start to 2015. We are not expecting that to happen this year in healthcare. It should be a much better starting point.

And so really addressing headcount both utilization, I would say, for utilization we would expect it to be in the full year range of 78%, 79% starting the year with hopefully some acceleration, again just like we saw this year.

I think from a headcount perspective, again, it's going to be a little bit different because just like you saw at the end of the year, there was a little bit of adjustment there as we have seen the pipeline just mix and transformation there.

We have made a few changes within the mix of the people and then I expect that to continue to start to grow a little bit in 2016, although again we tend to see our normal turnover. Usually the first half of the year is a little bit higher bonus payments and that's just consistent with past years as well.

So I would say it largely should track revenue but it should be a lot more evenly paced with a gradual upward right slope..

And the sequential trend in Business Advisory was very impressive and I get the impression, better than maybe you had expected a few months ago and looking at the sequential revenue change, where was the pickup?.

It was really on both sides of the practices. So the Business Advisory, the legacy part of the business with the broker-dealer had some success which had helped toward the end of the year. And you never know exactly on the timing with that but again collectively that was a matter of just realizing what we thought was already in the pipeline.

It didn't really change necessarily our expectations for 2016. So it wasn't like we were lower in 2016 because of that.

And then collectively, what's going on in the EPM&A practice is that just in general as businesses are really focusing on their need for better information from a financial perspective in terms of business intelligence, they are making investments and a little bit larger investments than we have seen in terms of just the historic mix.

We have a lot of clients who are definitely in the $1 million plus category now. And these engagements, sometimes start a little bit smaller. They are looking for just entry into the cloud, but oftentimes they end up expanding quite a bit more than you may initially expect.

So on both sides of the practice, I think they have a very good balance within the service offerings that they have and just right now, good momentum in the marketplace..

Thanks..

Thank you. [Operator Instructions]. Our next question comes from the line of Kevin Steinke of Barrington Research. Please proceed, sir..

Good afternoon. I believe you talked about Studer Group really driving most of the revenue growth in healthcare in 2016 and you also talked about your cautious outlook for the cost in clinical practice.

What about revenue cycle? Do you expect that practice to grow in 2016?.

Yes, we do, Kevin. Again, we think that practice is probably low to mid single-digit type practice on a conservative basis, but we do expect growth..

Okay. Fair enough. And you talked about the fact that in ELS, especially excluding the Workday revenue contribution that you expect, that your overall outlook for growth in 2016 in ELS is a little conservative.

Any reason for that conservatism in terms of projects winding down or anything like that? Or is it just the conservative outlook to start the year?.

I think it's more of the latter, Kevin. It was really the first time that in a while, we had really every practice in the business had really gone very well from the beginning and a lot of it is continuing, I think, into this year. We are just going to be cautious about how it all plays out just because of some of the uncertainty in the economy.

But if you look at the core demand for the services within ELS, it's really been very strong and we don't really see any changes as we enter 2016. So we are going to probably still stay a little bit conservative and let the year play out..

And Kevin, just as a reminder, the amount of backlog that we see at any given time, because the deal sizes tend to be a little bit smaller, we have a little bit less visibility in comparison to say Healthcare on the Education Life Sciences side of practice. But at this point, as Jim said, the signals have all continued to be pretty positive.

So we would hope that that guidance does prove conservative on Education Life Sciences..

And again part of what we react to is, we say the same thing for healthcare as well and frankly life sciences, but stress and strain in those industries are significant. So we are comfortable that there is going to be demand out there. We are going to cautious to see how it plays out. But certainly in ELS we have turned the corner nicely into 2016..

Okay. Great. And lastly, Mark, I think you talked about that the variance on the corporate costs takeout related to legal was about $3 million relative to your initial expectations.

So what are you assuming that you realize in 2016 in terms of the $11 million of cost savings? How much of that do you expect to get within your guidance?.

Kevin, I think realistically we will probably get $7 million or $8 million of the $11 million at this point and to some degree, just depending on how things wind up, as I said. I think we are pretty optimistic that we will get into the early part of the second quarter and start to be on a run rate that we expect.

So I would say, at this point that's a pretty good range right now in the $7 million or $8 million of the $11 million..

Okay. That's all I had. Thanks for taking the questions..

Thank you, Kevin..

And Mr. Roth, we have conclude the allotted time for this call. I would like to turn the conference back over to you..

Thank you for spending time with us this afternoon. We look forward to speaking with you again in April when we announce our first quarter results. Have a nice evening..

That concludes today's conference call. Thank you everyone for your participation..